Gesynta Pharma has announced the second closing of its Series B financing, bringing the total raised to SEK 347 million (€30 million).

The round now includes new investors HealthCap and Hadean Growth Fund, joining lead investor Innovestor Life Science. The funds will be used to prepare a Phase 2 proof-of-concept trial for vipoglanstat, the company’s lead candidate for endometriosis.

Vipoglanstat is a selective mPGES-1 inhibitor designed as a non-hormonal, non-opioid treatment for endometriosis, a chronic inflammatory disease that affects approximately 190 million women worldwide. Preclinical studies have shown that vipoglanstat reduces both pain and lesion development by targeting the enzyme mPGES-1, which is upregulated in endometriotic tissue.

Gesynta said the upcoming clinical trial will involve around 190 patients across multiple European countries. The company aims to use the data to inform a future Phase 3 program.

As part of the investment, three new board members have been appointed: Kristina Ekberg, partner at HealthCap; Cristina Csimma, an independent director with experience in clinical development; and David Colpman, a business development executive with a background in global partnerships.

“It is with great enthusiasm that we join this robust investor syndicate, dedicated to addressing a significant unmet medical need,” said Kristina Ekberg, partner at HealthCap.

Roger Franklin, chairman of Gesynta Pharma and partner at Hadean Ventures, added: “This second closing strengthens our strategy to advance vipoglanstat as an innovative non-hormonal option for endometriosis patients. The new board appointments bring valuable experience in clinical and commercial strategy as we prepare for the next phase of development.”

Endometriosis currently has limited treatment options, many of which rely on hormonal suppression or analgesics, and can carry significant side effects. Gesynta’s approach aims to offer an alternative with a different mechanism of action.